ENTRY       D10574                      Drug
NAME        Pembrolizumab (USAN);
            Pembrolizumab (genetical recombination) (JAN);
            Keytruda (TN)
PRODUCT     KEYTRUDA (Merck Sharp & Dohme LLC)
FORMULA     C6504H10004N1716O2036S46
EXACT_MASS  146195.9181
MOL_WEIGHT  146286.37
SEQUENCE    (Heavy chain)
            QVQLVQSGVE VKKPGASVKV SCKASGYTFT NYYMYWVRQA PGQGLEWMGG INPSNGGTNF
            NEKFKNRVTL TTDSSTTTAY MELKSLQFDD TAVYYCARRD YRFDMGFDYW GQGTTVTVSS
            ASTKGPSVFP LAPCSRSTSE STAALGCLVK DYFPEPVTVS WNSGALTSGV HTFPAVLQSS
            GLYSLSSVVT VPSSSLGTKT YTCNVDHKPS NTKVDKRVES KYGPPCPPCP APEFLGGPSV
            FLFPPKPKDT LMISRTPEVT CVVVDVSQED PEVQFNWYVD GVEVHNAKTK PREEQFNSTY
            RVVSVLTVLH QDWLNGKEYK CKVSNKGLPS SIEKTISKAK GQPREPQVYT LPPSQEEMTK
            NQVSLTCLVK GFYPSDIAVE WESNGQPENN YKTTPPVLDS DGSFFLYSRL TVDKSRWQEG
            NVFSCSVMHE ALHNHYTQKS LSLSLGK
            (Light chain)
            EIVLTQSPAT LSLSPGERAT LSCRASKGVS TSGYSYLHWY QQKPGQAPRL LIYLASYLES
            GVPARFSGSG SGTDFTLTIS SLEPEDFAVY YCQHSRDLPL TFGGGTKVEI KRTVAAPSVF
            IFPPSDEQLK SGTASVVCLL NNFYPREAKV QWKVDNALQS GNSQESVTEQ DSKDSTYSLS
            STLTLSKADY EKHKVYACEV THQGLSSPVT KSFNRGEC
            (Disulfide bridge: H22-H96, H134-L218, H147-H203, H226-H'226, H229-H'229, H261-H321, H367-H425, H'22-H'96, H'134-L'218, H'147-H'203, H'261-H'321, H'367-H'425, L23-L92, L138-L198, L'23-L'92, L'138-L'198)
  TYPE      Peptide
CLASS       Antineoplastic
             DG02938  Immune checkpoint inhibitor
REMARK      Therapeutic category: 4291
            ATC code: L01FF02
            Product: D10574<JP/US>
            Product (mixture): D13168<US>
EFFICACY    Antineoplastic, Immune checkpoint inhibitor, Anti-PD-1 antibody
  DISEASE   Melanoma [DS:H00038]
            Non-small cell lung cancer (PD-L1 expressed) [DS:H00014]
            Head and neck squamous cell carcinoma (PD-L1 expressed) [DS:H02420]
            Head and neck squamous cell carcinoma [DS:H02420]
            Hodgkin lymphoma [DS:H00007]
            Mediastinal large B-cell lymphoma [DS:H02434]
            Urothelial carcinoma [DS:H00022]
            Solid tumor (MSI-H or dMMR) [DS:H02421]
            Colorectal cancer (MSI-H) [DS:H00020]
            Gastric cancer (HER2 positive) [DS:H00018]
            Esophageal cancer (PD-L1 expressed) [DS:H00017]
            Cervical cancer (PD-L1 expressed) [DS:H00030]
            Hepatocellular carcinoma [DS:H00048]
            Merkel cell carcinoma [DS:H01555]
            Renal cell carcinoma [DS:H00021]
            Endometrial carcinoma (MSI-H or dMMR) [DS:H00026]
            Solid tumor (TMB-H) [DS:H02421]
            Cutaneous squamous cell carcinoma [DS:H00040]
            Breast cancer (triple negative, PD-L1 expressed) [DS:H00031]
  TYPE      Monoclonal antibody
TARGET      PDCD1 (PD1, CD279) [HSA:5133] [KO:K06744]
  PATHWAY   hsa04514(5133)  Cell adhesion molecule (CAM) interaction
            hsa04660(5133)  T cell receptor signaling pathway
            hsa05235(5133)  PD-L1 expression and PD-1 checkpoint pathway in cancer
INTERACTION  
BRITE       Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
             L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
              L01 ANTINEOPLASTIC AGENTS
               L01F MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES
                L01FF PD-1/PD-L1 (Programmed cell death protein 1/death ligand 1) inhibitors
                 L01FF02 Pembrolizumab
                  D10574  Pembrolizumab (USAN) &lt;JP/US&gt;
            USP drug classification [BR:br08302]
             Antineoplastics
              Monoclonal Antibody/Antibody-Drug Conjugate
               Anti-PD1 Antibodies
                Pembrolizumab
                 D10574  Pembrolizumab (USAN)
            Therapeutic category of drugs in Japan [BR:br08301]
             4  Agents affecting cellular function
              42  Antineoplastics
               429  Miscellaneous
                4291  Other Antitumors
                 D10574  Pembrolizumab (USAN); Pembrolizumab (genetical recombination) (JAN)
            Drug groups [BR:br08330]
             Antineoplastic
              DG02938  Immune checkpoint inhibitor
               D10574  Pembrolizumab
            Drug classes [BR:br08332]
             Antineoplastic
              DG02938  Immune checkpoint inhibitor
               D10574  Pembrolizumab
            Target-based classification of drugs [BR:br08310]
             Cell surface molecules and ligands
              Other cell surface molecules
               Immune checkpoints
                PDCD1 (PD1, CD279)
                 D10574  Pembrolizumab (USAN) &lt;JP/US&gt;
            New drug approvals in the USA [br08319.html]
             New molecular entities and new therapeutic biological products
              D10574
            New drug approvals in Europe [br08329.html]
             European public assessment reports (EPAR) authorised medicine
              D10574
            New drug approvals in Japan [br08318.html]
             Drugs with new active ingredients
              D10574
            New drug approvals in the USA, Europe and Japan [br08328.html]
             Approval dates by FDA, EMA and PMDA
              D10574
            Pharmacogenomic biomarkers [br08341.html]
             Somatic variations in targeted cancer therapies
              D10574
DBLINKS     CAS: 1374853-91-4
            PubChem: 254741536
///